Support and management for survivors of stem cell transplantation
Official title: AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation
Run by Copenhagen University Hospital, Rigshospitalet · NCT06281496 · Data updated 2026-11-12
This study is testing a new support program for people who have had stem cell transplants to see if it can help them feel better and improve their quality of life.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Copenhagen University Hospital, Rigshospitalet Academic / other |
| Locations | 1 site (Copenhagen) |
| Status | Recruiting |
| Started | November 1, 2024 |
| Main results expected | October 1, 2027 |
| Study ends | December 1, 2027 |
| Registry record updated | August 1, 2025 |
| Trial ID | NCT06281496 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adult patients over 18 years who have undergone allo-HSCT and are currently in outpatient follow-up without recurrent disease.
✕Probably not a fit
Patients with recurrence of disease or those requiring additional cancer treatment will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates a comprehensive intervention aimed at addressing late effects experienced by survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT). It is designed as a two-arm randomized controlled trial, including an internal pilot phase, to assess the impact of a multidisciplinary approach on health-related quality of life. Participants will be randomly assigned to either an intervention group receiving the AlloCare program or a control group. The goal is to improve survivorship-specific outcomes for these patients.
Why it matters
Potential benefit: If successful, this intervention could significantly enhance the quality of life for survivors of allo-HSCT by effectively managing late effects.
How similar studies have gone: While there have been studies addressing survivorship in cancer patients, this specific multimodal approach for allo-HSCT survivors is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (age\> 18 years) treated with myeloablative or non-myeloablative HSCT in outpatient follow-up without recurrent disease are eligible for inclusion. Exclusion Criteria: * Patients with recurrence or subsequent malignancy requiring cancer treatment or lack of access to email and the Internet will be excluded.
Where it's running
-
Rigshospitalet
Copenhagen, Denmark Recruiting
Study contacts
- Principal investigator: Mette Schaufuss Engedal, MSc — Rigshospitalet. Department of Hematology. Denmark
- Study coordinator: Mette Schaufuss Engedal, MSc
- Email: mette.schaufuss.engedal@regionh.dk
- Phone: +45 51896699
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using TBI and Melphalan for Second Stem Cell Transplantation in Blood Cancer Patients
This study is testing if using total body radiation and a drug called melphalan can help blood cancer patients who need a second stem cell transplant after their first one didn't work.
-
Observing patients with familial platelet disorder and RUNX1 variants
This study is looking to learn more about patients with a specific blood disorder caused by RUNX1 gene changes, including how it affects them and their families, to find better ways to treat and manage the condition.
-
Lower Dose Cyclophosphamide After Haploidentical Stem Cell Transplant
This trial tests whether giving half the usual amount of cyclophosphamide after haploidentical stem cell transplantation can still prevent GVHD in adults with blood cancers.
-
Chlorophyllin to reduce mouth sores before allogeneic stem cell transplant
This phase II study tests whether taking chlorophyllin by mouth can lower the chances and severity of mouth ulcers in patients aged 12–65 undergoing radiation-based conditioning before a first allogeneic stem cell transplant.
-
First-in-human test of DS3790a for hematological malignancies
This first-in-human trial will test DS3790a alone and with other drugs to see if it's safe, how it behaves in the body, and whether it helps adults with hematological malignancies.
-
18F‑Pentixafor PET imaging for blood cancers
This will test whether 18F‑Pentixafor PET scans help diagnose, stage, and check treatment response in adults with suspected or confirmed hematologic malignancies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.